Zynerba Pharmaceuticals delays data on genetic disorder drug study

Zynerba Pharmaceuticals

21/12/2022 12:11

Dec 21 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O 
said on Wednesday it is delaying the timeline for reporting data
from a late-stage study of its experimental drug for a genetic
disorder due to difficulties in enrolling patients. 
    It now expects to present results from the trial in first
half of 2024 from second half of 2023.
 (Reporting by Khushi Mandowara in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Khushi.Mandowara@thomsonreuters.com;))